GLP-1 receptor agonists are the most consequential drug class to emerge in obesity and type-2 diabetes since metformin. The category started with exenatide and liraglutide, broke commercial ceilings with semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), and is now expanding into orals (orforglipron, oral semaglutide), triple agonists (retatrutide), and amylin combinations (cagrisema, eloralintide).
The signal worth tracking has shifted. Weight loss alone is no longer the headline — secondary indications are. SELECT showed a 20% drop in major adverse cardiovascular events for non-diabetic adults with obesity. A Mass General Brigham analysis in JAMA reported 42–58% lower heart-failure hospitalizations in HFpEF. AAN 2026 added migraine, dementia incidence, and Parkinson's signals to the growing list. The Phase 3 EVOKE Alzheimer's trial, by contrast, missed its endpoint.
Gallup's July 7, 2026 poll release documented the first large-population evidence that GLP-1 uptake is bending the US obesity curve: 11% of US adults now take a GLP-1 for weight loss (up from 3% in 2024 and 8% in 2025), and the US adult obesity rate has drifted from a 2022 peak of 39.9% down to 36.4% in 2026. Awareness climbed from 80% to 91% over the same span. Browse the latest below, or filter by drug at #semaglutide, #tirzepatide, #orforglipron, and #retatrutide.
Researchers at Tufts University and UT Southwestern reported in Obesity Science & Practice on October 7, 2026 a pilot randomized trial of 39 adults who had lost weight on GLP-1 drugs and were stopping them, assigned to usual care (14), a digital wellness app (12), or medically tailored meals (13). Over the first four months off the drug, both the app and meal groups gained less weight than the control group, by 7.16 and 7.17 percentage points of body weight. Weight was an exploratory outcome, measured with Bluetooth scales at home, and the authors said larger and longer trials are needed.
A UT Southwestern study published October 7, 2026 in Diabetes, Obesity and Metabolism compared 73,592 matched pairs of veterans with type 2 diabetes who started a GLP-1 drug or a DPP-4 inhibitor, an older diabetes pill, between 2006 and 2021. Over about 27 months, the GLP-1 group had a 13% lower fall rate (incidence rate ratio 0.87) and slightly less worsening on a frailty index. The link weakened in people who were already severely frail, and the observational design cannot prove the drugs caused the difference.
Researchers at Hebrew University and Hadassah Medical Center reported in Diabetes, Obesity and Metabolism on October 7, 2026 a records study of 4,554 matched adults with type 2 diabetes and stage 3 or 4 chronic kidney disease who started a GLP-1 drug or tirzepatide, or finerenone, a non-steroidal kidney drug. Kidney failure or dialysis occurred in 4.8% versus 6.0% within 2.5 years (hazard ratio 0.71), but the absolute risk difference of 1.14 percentage points was not statistically clear. Albuminuria, a key kidney measure, was missing for most people, so the authors warned of residual confounding.
The World Health Organization published its first guidelines on managing obesity in children and in adolescents on October 7, 2026. For children up to age 9, it makes a strong recommendation against weight-loss medicines, based on low-quality evidence. For ages 10 to 19, it conditionally suggests medicines only for teens who have obesity-related complications, such as type 2 diabetes or uncontrolled high blood pressure, and whose weight has not improved after a supervised diet, exercise, and behavior program lasting at least six months; treatment should be given by a specialist team with long-term follow-up. WHO's evidence review found mostly short trials and noted that teens taking GLP-1 drugs or orlistat stopped more often because of side effects.
An online survey of 760 U.S. hepatologists and gastroenterologists, endocrinologists, and primary care clinicians, conducted from November 2024 to January 2025 and published October 6, 2026 in Clinical and Translational Gastroenterology, found that 76.8% were very or extremely familiar with the GLP-1 receptor, compared with 53.9% for the GIP receptor and 30.1% for the glucagon receptor. Most still expected each type of agonist to help people with MASH: 90.3% for GLP-1, 75.9% for GIP, and 87.0% for glucagon receptor agonists. One author is a Boehringer Ingelheim employee; Boehringer is developing survodutide, a GLP-1 and glucagon dual agonist, for MASH.
The Lancet Obstetrics, Gynaecology & Women's Health published two papers on GLP-1 drugs in women on Tuesday, September 29, 2026. A systematic review, meta-analysis, and international consensus statement led by Sarah Dib pooled seven studies covering more than 43,000 exposed women with diabetes and found no clear link to congenital anomalies, preterm birth, stillbirth, or preeclampsia; early pregnancy loss, which counted miscarriages and terminations together, was 31% more common among exposed women in two studies, a result the authors said needs caution. A companion review led by Claire Meek of the Leicester Diabetes Research Centre said the drugs' global rollout has outpaced guidance for women and cited studies in which most long-term users fell short on vitamin D, iron, and other nutrients.
A retrospective study from Taipei Medical University, published in BMC Gastroenterology on Saturday, October 3, 2026, used the U.S. TriNetX health records network to compare 4,870 adults with type 2 diabetes who had a GLP-1 receptor agonist prescription in the three months before a colonoscopy with 4,870 matched adults who did not. Within 12 months, 11.0% of GLP-1 users had a repeat colonoscopy versus 8.9% of nonusers (hazard ratio 1.37), and the gap was similar after June 2023 society guidance on holding the drugs before procedures. The authors used a repeat colonoscopy as a stand-in for poor bowel preparation, which the study did not measure directly, and described the absolute difference as modest.
A cross-sectional, case-control study presented at the European Academy of Dermatology and Venereology Congress in Vienna (September 30 to October 3, 2026) compared 575 GLP-1 receptor agonist users with 1,329 people with type 2 diabetes, obesity, or both who had never taken the drugs, in France, the U.S., Brazil, and Mexico. Users reported nail detachment far more often (39% vs. 9%), along with nail discoloration (46% vs. 17%) and unusual hair loss (50% vs. 34%); after adjustment, nail detachment and discoloration remained roughly two to three times as frequent. The symptoms were self-reported, about half of users said they had nail problems before treatment, and the design cannot show that the drugs cause these changes; Gizmodo reported that the work was funded by Pierre Fabre.
The American Diabetes Association and the European Association for the Study of Diabetes published their 2026 consensus report on managing type 2 diabetes in non-pregnant adults on Friday, October 2, 2026, in Diabetes Care and Diabetologia, presenting it at EASD in Milan; it updates the 2022 report. Chaired by John Buse and Melanie Davies, it calls for earlier use of glucose-lowering medicines to prevent complications and earlier use of SGLT2 inhibitors and GLP-1-based therapies to modify disease and reduce complication risk, tailored to each person's cardiovascular and kidney risk. It also sets individualized weight-management goals and gives more attention to coexisting conditions such as metabolic dysfunction-associated steatotic liver disease (MASLD).
Researchers led by Karen Hvid of Copenhagen University Hospital, Herlev, are presenting at the EASD annual meeting in Milan an analysis of 313,145 adults with a BMI of 25 or higher and no coronary heart disease or diabetes, drawn from the Copenhagen General Population Study and UK Biobank and followed for up to 18 and 15 years. About 44% (Copenhagen) and 48% (UK Biobank) of people with a BMI of 25 to 26.9, who fall below current GLP-1 weight-loss eligibility, had elevated remnant cholesterol, low-grade inflammation, or both. Those with both markers and no drug indication were 41% (Copenhagen) and 47% (UK Biobank) more likely to develop heart disease than people without an indication and with healthy levels, compared with increases of 41% and 35% among people who already qualify for the drugs. The findings are observational, and the authors said clinical trials are needed.
Roche announced on Tuesday, September 22, 2026 that enicepatide (CT-388), an investigational once-weekly GLP-1/GIP receptor agonist, met both primary endpoints in the randomized, placebo-controlled Phase 2 CT-388-104 trial in 447 adults with type 2 diabetes and overweight or obesity. At the highest titrated dose of 24 mg, HbA1c fell 2.65 percentage points from a baseline of 8.1%, mean weight loss was 15.5% at 48 weeks with no plateau, and 90% of patients on that dose reached an HbA1c of 6.5% or lower. Discontinuation due to adverse events was 2.0% across enicepatide arms versus 0.0% on placebo, and side effects were mostly mild-to-moderate gastrointestinal. Roche's announcement did not give placebo results for weight or HbA1c; the company plans a Phase 3 glycemic-control program and cardiovascular outcomes trials in the first half of 2027, alongside the ongoing ENITH-1 and ENITH-2 weight-management trials.
Viking Therapeutics announced on Thursday, September 24, 2026 that it priced 7,857,143 shares of common stock at $35.00 per share (about $275 million) and $225.0 million of 2.00% convertible senior notes due October 15, 2032, after proposing the offerings on September 23. The notes convert at about $50.75 per share, roughly a 45% premium to the stock price, and underwriters have options on another 1,178,571 shares and $33.75 million of notes. Viking estimates net proceeds of about $258.2 million from the stock and $218.0 million from the notes, for its VK2735 and VK3019 programs and general purposes. The offerings are expected to settle on September 25, three days after Viking reported VK2735 maintenance-study results.
An updated systematic review by Areesha Moiz, Mark Eisenberg, and colleagues, published online September 1, 2026 in the Annals of Internal Medicine, covered 38 randomized trials in 25,816 adults with overweight or obesity and without diabetes, adding 14 trials to the authors' earlier review. Among marketed drugs, the highest placebo-subtracted weight loss reported was 5.8% for liraglutide, 14.8% for subcutaneous semaglutide, 14.3% for oral semaglutide, 12.4% for orforglipron, and 19.0% for tirzepatide; emerging agents reached 23.9% with amycretin and 22.1% with retatrutide. Gastrointestinal adverse events occurred in 76.0% of patients on GLP-1 drugs versus 40.1% on placebo, and discontinuation for adverse events was 10.7% versus 3.4%. The authors said heterogeneity prevented a pooled quantitative analysis, so these figures are the highest values from individual trials rather than combined estimates.
Viking Therapeutics reported on Tuesday, September 22, 2026 topline results from a double-blind, placebo-controlled maintenance study of VK2735, its dual GLP-1/GIP receptor agonist, in about 180 adults with a BMI of 30 or higher. After 21 weeks of weekly dosing, placebo-adjusted weight loss was 16% to 19% across VK2735 cohorts; an exploratory cohort on 17.5 mg weekly (n=13) reached about 22% weight loss from baseline at week 33. In the 12-week randomized maintenance phase, every-other-week dosing kept up to 97% of mean weight loss and monthly dosing up to 90%, compared with 61% for patients switched to placebo. Viking said gastrointestinal adverse event rates during maintenance were similar to placebo, and it plans a second part of the study to test oral maintenance regimens.
Novo Nordisk shares fell about 8% in both Copenhagen and New York on Monday, September 21, 2026, the day of its London Capital Markets Day, according to GEN. BMO Capital Markets analyst Evan Seigerman wrote that Novo is "targeting 2026-2030 revenue growth in line with industry peers, likely underwhelming for investors," and noted that consensus already models about 3.53% annual growth for Novo against roughly 3.65% for pharma peers, so the target appeared priced into Wall Street estimates. The company used the event to set 2030 ambitions that included more than five potential blockbuster launches.
Novo Nordisk set out its 2030 ambitions at its Capital Markets Day in London on Monday, September 21, 2026: launch more than five multi-blockbusters, run at least five Phase 3 programs in obesity and diabetes and at least five in other therapy areas, serve more than 60 million patients, build capacity to serve 10 times more people with obesity on oral GLP-1, keep a broadly stable operating margin, and deliver 2026-2030 revenue growth in line with industry peers. It also targets more than DKK 150 billion (about $23 billion) in pipeline sales in 2035, and it said the ambitions are not financial guidance. Shares fell as much as 9% and were down 4.7% by 11:24 GMT, BNN Bloomberg reported, as management faced questions on pricing and dealmaking. Management said CagriSema would launch early next year, followed by standalone cagrilintide and high-dose CagriSema in 2028, with zenagamtide planned to launch in oral and injectable forms at the same time; BNN Bloomberg also reported a plan to scale manufacturing tenfold to supply 15 million patients with oral obesity therapies by the end of the decade.
Novo will hold its Capital Markets Day in London on Monday, September 21, 2026, with CEO Mike Doustdar presenting the corporate strategy. A TIKR preview published September 10 noted that the U.S.-listed shares closed at $44.56 on September 9, nearer their 12-month low of $35.12 than their high of $64.16. The preview put total Wegovy pill prescriptions past five million, with the latest million added in four weeks, and the pill's share of the U.S. oral obesity market at about 90%. It also pointed to a U.S. obesity decision on CagriSema at the end of 2026 and to semaglutide losing exclusivity in markets such as Canada and Brazil in the second half of 2026. The event follows Novo's announcement that it will drop 'Nordisk' from its name in day-to-day use.
Healthline reported on Friday, September 18, 2026 on a study by nference researchers, including Venky Soundararajan, published August 31 in Biology Methods & Protocols. The study followed 1,016 people who stayed on 2.5 mg tirzepatide for at least six months and 814 who took at least three 0.25 mg semaglutide doses over at least six months; at 12 months, weight loss averaged about 5.5% and 2.2%, respectively. At 24 months, people on sustained low-dose semaglutide had lower rates of constipation (23.3% vs 36.3%), nausea (39.7% vs 50.1%), and low blood pressure (1.7% vs 5.4%) than people on higher doses. Mir Ali, MD, of MemorialCare told Healthline that most patients will need some dose escalation to keep losing weight, and the article noted that dosing outside approved schedules is not FDA- or manufacturer-approved.